Gilead Sciences 10-Qquarter ended 2026-09-30

Executive Summary

Gilead sells prescription medicines for people with HIV, liver disease and cancer, earning revenue primarily from product sales through wholesalers. It is expanding HIV prevention while buying oncology and autoimmune-disease programs to broaden its business beyond HIV. Q3 revenue rose 6.8% to $8.30B, led by HIV medicines and Trodelvy, but competition weakened cell therapy. Acquisitions and a failed lung-cancer program produced a 9M net loss of $(6.05)B despite strong operating cash flow. For investors, the opportunity is a broader growth portfolio; the test is whether new medicines can justify acquisition spending before pricing pressure hits Biktarvy.

What's Happening in the Business

HIV growth strengthened as Biktarvy, Descovy and Yeztugo benefited from demand, higher realized prices and favorable inventory movements. Gilead is extending its treatment and prevention franchise: Bixlenvo received approval for virologically suppressed adults, and the FDA accepted an application for Yeztugo’s potential once-weekly oral formulation.

Expansion outside HIV is uneven. Livdelzi drove liver-disease growth, and Hepcludex received accelerated approval for chronic hepatitis delta. Trodelvy gained U.S. first-line metastatic triple-negative breast cancer approval, but Gilead and Merck discontinued the EVOKE-03 lung-cancer study. Cell-therapy sales continued falling under competitive pressure despite Tecartus receiving full approval for adult relapsed/refractory mantle cell lymphoma.

Gilead acquired Arcellx, Tubulis and Ouro Medicines, adding anito-cel, antibody-drug conjugates and the autoimmune-disease program gamgertamig. These purchases deepen its development pipeline rather than immediately replacing HIV revenue. In October, it also agreed to buy PepStar’s oral IL-23R program for $1.28B upfront, with closing expected in Q4.

Key Financial Highlights

Q3 and 9M ended 9/30/2026; changes are Y/Y.

• HIV drivers: Q3 Biktarvy sales reached $4.06B, +10%; Descovy $1.05B, +49%; and Yeztugo $305M vs $39M. HIV growth accelerated relative to 9M, although favorable inventory movements mean sales growth is not purely patient-demand growth.
• Other product drivers: Livdelzi reached $203M, +93%, offsetting lower hepatitis C sales; fewer COVID-19 hospitalizations depressed Veklury, while higher demand supported Trodelvy.
• Margins and spending: Q3 product gross margin reached 81.0% from 78.6%, primarily because a royalty obligation expired. R&D rose 19% to $1.61B and selling, general and administrative expense rose 21% to $1.64B, reflecting development, promotion, integration and other costs.
• Acquisition accounting: 9M acquired research expense was $11.3B vs $485M. A separate $1.75B impairment eliminated the lung-cancer research asset’s value after EVOKE-03 stopped; this was lost expected future value, not a cash payment that quarter.
• Earnings volatility: Other results swung to $130M of Q3 expense from $569M of income, mainly as equity-investment gains became losses and interest income fell.
• Cash and funding: The loss included large noncash charges, while $11.3B of acquisition cash payments were investing outflows, not operating outflows. Cash ended at $6.44B; total debt, net, rose 5.2% to $26.2B, and tangible equity was negative $8.78B.

Risk Assessment

• HIV pricing and exclusivity: Biktarvy’s Medicare price, effective 1/1/2028, is substantially below its current Medicare price; patent challenges to Descovy and other products add exposure to lower prices and generic competition.
• Pipeline and capital allocation: The lung-cancer write-off demonstrates late-stage failure risk, while acquisition spending and negative tangible equity leave less financial flexibility if purchased programs disappoint.
• Cell-therapy execution: Competitive pressure, complex patient-specific manufacturing and hospital reimbursement constraints could further limit Yescarta and Tecartus adoption.
• Litigation: HIV antitrust appeals remain unresolved, and Aetna’s remaining Truvada/Atripla claims are scheduled for trial in January 2027, creating potential material liability.

What to Watch

• HIV expansion: Yeztugo’s oral application has a management-reported FDA target date of 2/2/2027; approval and sustained uptake would strengthen prevention growth, while delays or inventory reversals would weaken it.
• Oncology delivery: Watch whether Trodelvy’s new indication sustains growth and whether acquired anito-cel progresses, versus further setbacks and continued cell-therapy erosion.
• Pricing resilience: Later filings should show how Biktarvy’s negotiated Medicare price affects realized pricing and whether newer HIV products offset that pressure.
• Acquisition funding: Operating cash generation must support pipeline spending and debt needs; sustained cash generation would preserve flexibility, while further borrowing would increase dependence on acquisition success.